News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MabCure, Inc. Generates Tumor Specific Antibodies against Prostate Cancer Which Could Lead to a Blood/Urine Diagnostic Test for Prostate Cancer



11/8/2010 12:07:54 PM

NEW YORK--(BUSINESS WIRE)--Biotechnology company MabCure, Inc. (OTCBB: MBCI) today announced that it has generated a panel of 10 novel monoclonal antibodies (MAbs) against prostate cancer. These MAbs were selected from more than 30,000 MAbs produced by MabCure’s proprietary technology.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES